Neoplasms

All Conditions

Rare Diseases

Neuroendocrine Tumors

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms by Histologic Type

Neoplasms, Nerve Tissue

Neuroendocrine Tumor

Neuroepithelioma

Anti-Infective Agents

Antineoplastic Agents

All Drugs and Chemicals

Thalidomide

Temozolomide

Immunosuppressive Agents

Immunologic Factors

Anti-Bacterial Agents

Angiogenesis Inhibitors

Growth Inhibitors

Antineoplastic Agents, Alkylating

Alkylating Agents

Temodar

Matthew H. Kulke, MD

The purpose of this study is to find out what effects, good or bad, that thalidomide and temodar have on patients with neuroendocrine tumors.

* Patients will receive thalidomide orally once daily continuously unless they experience significant side effects. Temodar is given orally once a day for one week, followed by a one week break period. This one week on/one week off schedule will continue for the duration of treatment unless there are significant side effects.
* After eight weeks (2 cycles) a CT scan will be performed to see how the treatment has affected the patient's tumor. Patients will continue taking the study drug unless there is evidence of tumor growth.
* Regular blood tests will be done weekly during the first two months to make sure that the treatment is not resulting in serious side effects. If there are no side effects during the first two months, the blood tests may decrease in frequency to every two weeks.
* Immediately after the patient has completed the study they will be evaluated by physical exam, blood work, and a CT scan. The follow-up will consist of clinic visits and phone calls every 3 months.

Thalidomide in Combination With Temodar in Patients With Neuroendocrine Tumors

A Phase II Study of Thalidomide in Combination With Temodar in Patients With Metastatic Neuroendocrine Tumors

Brigham and Women's Hospital

Massachusetts General Hospital

Beth Israel Deaconess Medical Center

Dana-Farber Cancer Institute

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Thalidomide in Combination With Temodar in Patients With Neuroendocrine Tumors	NCT00165230	Neuroendocrine ...	Thalidomide Temodar	18 Years -	Dana-Farber Cancer Institute
Thalidomide in Combination With Temodar in Patients With Neuroendocrine Tumors	NCT00165230	Neuroendocrine ...	Thalidomide Temodar	18 Years -	Dana-Farber Cancer Institute

Spots Global Cancer Trial Database for unresectable neuroendocrine tumor